← All trials
NCT06071936
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 15, 2023
- Primary completion
- Sep 30, 2024
- Completion date
- Dec 31, 2024
- First posted
- Oct 10, 2023
- Last posted
- Oct 10, 2023
- Enrollment
- 558
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Apurano Pharmaceuticals GmbHLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.